ES2500067T3 - Compuesto bicíclico y uso del mismo para fines médicos - Google Patents

Compuesto bicíclico y uso del mismo para fines médicos Download PDF

Info

Publication number
ES2500067T3
ES2500067T3 ES10804397.7T ES10804397T ES2500067T3 ES 2500067 T3 ES2500067 T3 ES 2500067T3 ES 10804397 T ES10804397 T ES 10804397T ES 2500067 T3 ES2500067 T3 ES 2500067T3
Authority
ES
Spain
Prior art keywords
medical purposes
bicyclic compound
bicyclic
compound
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10804397.7T
Other languages
English (en)
Inventor
Tohru Kambe
Toru Maruyama
Shinsaku Yamane
Satoshi Nakayama
Kousuke Tani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2500067T3 publication Critical patent/ES2500067T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/902—Method of implanting
    • Y10S623/905—Eye

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)
  • Image Processing (AREA)

Abstract

3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-Difluorofenoxi)-3-hidroxi-1-buten-14]-7-hidroxioctahidro-2Hciclopenta[ b]oxepin-3-il}butanoato de 2-propanilo o un solvato del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66

Claims (1)

  1. imagen1
ES10804397.7T 2009-07-28 2010-07-27 Compuesto bicíclico y uso del mismo para fines médicos Active ES2500067T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009175246 2009-07-28
JP2009175246 2009-07-28
PCT/JP2010/062587 WO2011013651A1 (ja) 2009-07-28 2010-07-27 二環式化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
ES2500067T3 true ES2500067T3 (es) 2014-09-30

Family

ID=43529306

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13003505.8T Active ES2567328T3 (es) 2009-07-28 2010-07-27 Compuesto bicíclico y uso del mismo para fines médicos
ES10804397.7T Active ES2500067T3 (es) 2009-07-28 2010-07-27 Compuesto bicíclico y uso del mismo para fines médicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13003505.8T Active ES2567328T3 (es) 2009-07-28 2010-07-27 Compuesto bicíclico y uso del mismo para fines médicos

Country Status (20)

Country Link
US (10) US8614340B2 (es)
EP (2) EP2460801B1 (es)
JP (3) JP5652397B2 (es)
KR (1) KR101768235B1 (es)
CN (1) CN102498105B (es)
AU (1) AU2010279183B2 (es)
BR (1) BR112012001797B1 (es)
CA (1) CA2767083C (es)
DK (2) DK2653468T3 (es)
ES (2) ES2567328T3 (es)
HU (1) HUE028874T2 (es)
IL (1) IL217342A (es)
MX (1) MX2012000889A (es)
NZ (1) NZ597626A (es)
PL (2) PL2460801T3 (es)
PT (1) PT2460801E (es)
RU (1) RU2540330C2 (es)
TW (1) TWI466877B (es)
WO (1) WO2011013651A1 (es)
ZA (1) ZA201200797B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2653468T3 (en) 2009-07-28 2016-06-06 Ono Pharmaceutical Co Bicyclic compound AND USE THEREOF FOR MEDICAL PURPOSES
US9029574B2 (en) 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
WO2012102355A1 (ja) 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
US9944217B2 (en) 2013-02-11 2018-04-17 Ferno-Washington, Inc. Equipment mounting system
ES2693255T3 (es) * 2014-02-27 2018-12-10 Ono Pharmaceutical Co., Ltd. Compuesto que presenta actividad agonista de EP2 selectiva
JP6773035B2 (ja) * 2015-07-23 2020-10-21 小野薬品工業株式会社 Ｅｐ２アゴニスト活性を有する化合物
US20190142811A1 (en) * 2016-04-01 2019-05-16 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
EP3480191B1 (en) * 2016-06-30 2021-09-01 ONO Pharmaceutical Co., Ltd. Method for producing bicyclic compound
EP4338751B1 (en) * 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
SG11202005620QA (en) * 2017-12-21 2020-07-29 Ono Pharmaceutical Co THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER
WO2019124489A1 (ja) * 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
CN116159601B (zh) * 2019-03-15 2024-07-23 博瑞生物医药（苏州）股份有限公司 艾日布林中间体及其制备方法
AU2019466972B2 (en) * 2019-09-19 2023-07-06 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
ES3015621T3 (en) 2019-12-31 2025-05-06 Ind Tech Res Inst Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and use of the same
WO2021145356A1 (ja) * 2020-01-15 2021-07-22 参天製薬株式会社 近視の治療、近視の予防および／または近視の進行抑制のための医薬組成物
KR20230051199A (ko) * 2020-08-13 2023-04-17 산텐 세이야꾸 가부시키가이샤 세페타프로스트를 함유하는 의약 제제
CN116947725B (zh) * 2022-04-14 2026-03-27 广州楷石医药有限公司 曲伏前列素的合成方法
EP4512404A4 (en) * 2022-04-22 2026-04-29 Santen Pharmaceutical Co Ltd Composition intended for ophthalmic use containing sepetaprost
TW202539693A (zh) * 2024-01-24 2025-10-16 日商參天製藥股份有限公司 用以使罹患青光眼或高眼壓症之患者於夜間睡眠時之眼壓下降之含有賽佩普斯特(Sepetaprost)之點眼液

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425417A (en) * 1890-04-15 Wall-paper exhibitor
JPS5411311B2 (es) 1973-08-11 1979-05-14
IL51189A (en) 1976-02-04 1985-08-30 Upjohn Co Prostaglandin analogs
FI71138C (fi) 1976-12-31 1986-11-24 Erba Farmitalia Foerfarande foer framstaellning av terapeutiskt aktiva bisykliska prostaglandiner
US4490537A (en) 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4169841A (en) * 1977-04-19 1979-10-02 The Upjohn Company Alkenyl-substituted 9-deoxy-6,9-α-epoxymethano-PG analogs
CA1184906A (en) 1977-04-19 1985-04-02 Roy A. Johnson 9-deoxy-5,9-epoxy-prostaglandins
US4209615A (en) * 1977-04-19 1980-06-24 The Upjohn Company Phenyl-substituted 9-deoxy-6,9α-epoxymethano-PG analogs
US4490548A (en) 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
JPS5573678A (en) 1978-11-29 1980-06-03 Ono Pharmaceut Co Ltd Simultated compound of thio-prostaglandin i1, its preparation and drug composition containing it as active ingredient
DE2947526A1 (de) 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge
JPS6468367A (en) 1987-09-08 1989-03-14 Ono Pharmaceutical Co Novel bicyclic ethers or lactones
DE60039727D1 (de) 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
JP5037780B2 (ja) 2003-05-23 2012-10-03 三菱化学株式会社 活性エネルギー線硬化性組成物及びハードコートフィルム
US7906552B2 (en) * 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
BRPI0713587A2 (pt) * 2006-06-20 2012-10-23 Allergan Inc descrição de compostos terapêuticos da invenção
JP5573678B2 (ja) 2008-12-10 2014-08-20 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子の製造方法、有機エレクトロルミネッセンス素子
JP5384959B2 (ja) 2009-01-28 2014-01-08 セミコンダクター・コンポーネンツ・インダストリーズ・リミテッド・ライアビリティ・カンパニー 電子回路
US9280875B2 (en) 2009-03-06 2016-03-08 Zynga Inc. Virtual playing chips in a multiuser online game network
DK2653468T3 (en) 2009-07-28 2016-06-06 Ono Pharmaceutical Co Bicyclic compound AND USE THEREOF FOR MEDICAL PURPOSES
CN106928227B (zh) 2010-07-15 2020-06-30 浙江奥翔药业股份有限公司 恩替卡韦的合成方法及其中间体化合物
WO2012102355A1 (ja) 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
US9029574B2 (en) * 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
WO2016022879A1 (en) * 2014-08-07 2016-02-11 Georgia-Pacific Chemicals Llc Strengthening resins for paper products
EP3480191B1 (en) * 2016-06-30 2021-09-01 ONO Pharmaceutical Co., Ltd. Method for producing bicyclic compound

Also Published As

Publication number Publication date
CN102498105B (zh) 2014-04-02
IL217342A0 (en) 2012-02-29
WO2011013651A1 (ja) 2011-02-03
DK2653468T3 (en) 2016-06-06
US20210169842A1 (en) 2021-06-10
JP6149975B2 (ja) 2017-06-21
US8962868B2 (en) 2015-02-24
CN102498105A (zh) 2012-06-13
AU2010279183B2 (en) 2015-10-29
BR112012001797B1 (pt) 2020-04-07
RU2012107109A (ru) 2013-09-10
US20190111019A1 (en) 2019-04-18
US11617733B2 (en) 2023-04-04
US8614340B2 (en) 2013-12-24
US20230190698A1 (en) 2023-06-22
HUE028874T2 (en) 2017-01-30
US10940134B2 (en) 2021-03-09
US20200093781A1 (en) 2020-03-26
HK1170487A1 (en) 2013-03-01
EP2460801A4 (en) 2013-01-02
RU2540330C2 (ru) 2015-02-10
US20160287551A1 (en) 2016-10-06
PL2460801T3 (pl) 2014-11-28
US20140073676A1 (en) 2014-03-13
PT2460801E (pt) 2014-08-29
EP2653468B1 (en) 2016-02-24
US20120122964A1 (en) 2012-05-17
KR101768235B1 (ko) 2017-08-14
MX2012000889A (es) 2012-02-13
JP5935857B2 (ja) 2016-06-15
EP2460801B1 (en) 2014-06-25
ZA201200797B (en) 2012-10-31
EP2460801A1 (en) 2012-06-06
JP2016188217A (ja) 2016-11-04
BR112012001797A2 (pt) 2017-05-16
NZ597626A (en) 2013-03-28
US9388157B2 (en) 2016-07-12
JP5652397B2 (ja) 2015-01-14
US20180116995A1 (en) 2018-05-03
CA2767083A1 (en) 2011-02-03
CA2767083C (en) 2017-05-16
JP2015052011A (ja) 2015-03-19
US10201520B2 (en) 2019-02-12
US9889114B2 (en) 2018-02-13
PL2653468T3 (pl) 2016-08-31
US20150112079A1 (en) 2015-04-23
ES2567328T3 (es) 2016-04-21
KR20120038986A (ko) 2012-04-24
JPWO2011013651A1 (ja) 2013-01-07
US12201603B2 (en) 2025-01-21
IL217342A (en) 2016-03-31
AU2010279183A1 (en) 2012-02-02
TWI466877B (zh) 2015-01-01
TW201109311A (en) 2011-03-16
US20250099419A1 (en) 2025-03-27
EP2653468A1 (en) 2013-10-23
DK2460801T3 (da) 2014-09-22

Similar Documents

Publication Publication Date Title
ES2546866T3 (es) Polimorfos de darunavir
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
IN2014CN04037A (es)
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
EA201000774A1 (ru) Ингибиторы бета-лактамазы
EP4034901A4 (en) PARALLEL MAXWELL IMAGING
WO2015061572A8 (en) Inhibitors of the fibroblast growth factor receptor
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2014000450A1 (es) Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros.
WO2013059530A3 (en) Peptidomimetic macrocycles
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
UY34191A (es) ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?.
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
ES2642085T3 (es) Procedimientos anaeróbicos de tratamiento de lodos
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
ES2534911T3 (es) Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
EA201290954A1 (ru) Композиция для топического применения
ES2508117T3 (es) Uso del butanoato de 4-[etil(dimetil)amonio)] en el tratamiento de la enfermedad cardiovascular